Scientific Publications Archives

ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results From the Phase 1 TRAVERSE Study

Post author:andrewkaretas
Post published:June 1, 2025
Post category:CD70 Scientific Publications

Read more about the article ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts) With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts) With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

Post author:andrewkaretas
Post published:June 1, 2025
Post category:CD19 Scientific Publications

$Read more about the article Allogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies$

Allogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

Post author:andrewkaretas
Post published:February 12, 2025
Post category:CD19 Scientific Publications

$Read more about the article Supplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies$

Supplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies

Post author:andrewkaretas
Post published:February 12, 2025
Post category:CD19 Scientific Publications

Read more about the article Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Post author:andrewkaretas
Post published:December 9, 2024
Post category:CD19 Scientific Publications

Read more about the article Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases

Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases

Post author:andrewkaretas
Post published:November 18, 2024
Post category:Dual Scientific Publications

Read more about the article ALLO-316 in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Updated Safety and Efficacy From the Phase 1 TRAVERSE Multicenter Study

ALLO-316 in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Updated Safety and Efficacy From the Phase 1 TRAVERSE Multicenter Study

Post author:andrewkaretas
Post published:November 7, 2024
Post category:CD70 Scientific Publications

Cellular Mechanisms Affecting Allogeneic CAR T Cell Expansion and Rejection in Large B-cell Lymphoma^*

Post author:andrewkaretas
Post published:December 11, 2023
Post category:CD19 Scientific Publications

*In collaboration with The University of Texas MD Anderson Cancer Center.

$Read more about the article ALLO‑647 for Lymphodepletion in the Allogeneic CAR T Cell Setting: Safety Experience With ALLO‑501‌ /‌ 501A in Patients With Relapsed / Refractory Large B-Cell and Follicular Lymphomas$

ALLO‑647 for Lymphodepletion in the Allogeneic CAR T Cell Setting: Safety Experience With ALLO‑501‌ /‌ 501A in Patients With Relapsed / Refractory Large B-Cell and Follicular Lymphomas

Post author:andrewkaretas
Post published:December 9, 2023
Post category:ALLO-647 Scientific Publications

Preclinical Evaluation of Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR

Post author:andrewkaretas
Post published:November 2, 2023
Post category:Dual PLATFORM Scientific Publications

ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results From the Phase 1 TRAVERSE Study

ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts) With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

Allogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

Supplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies

Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases

ALLO-316 in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Updated Safety and Efficacy From the Phase 1 TRAVERSE Multicenter Study

Cellular Mechanisms Affecting Allogeneic CAR T Cell Expansion and Rejection in Large B-cell Lymphoma^*

ALLO‑647 for Lymphodepletion in the Allogeneic CAR T Cell Setting: Safety Experience With ALLO‑501‌ /‌ 501A in Patients With Relapsed / Refractory Large B-Cell and Follicular Lymphomas

Preclinical Evaluation of Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR

CONNECT

CONNECT